Today: 23 June 2026
Browse Category

Pharmaceuticals 30 December 2025 - 1 January 2026

AbbVie is acquiring Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal is expected to close in the third quarter and will bring AbbVie zumilokibart, an experimental long-acting drug for atopic dermatitis and other immune diseases. Apogee claims its top eczema drug could significantly reduce injection frequency compared to Dupixent, with Phase 3 trials planned for this year. Pfizer shares declined over the past week after CFO Dave Denton announced he will step down in August, with Cecile Guegan set to become interim CFO. Despite the leadership change, Pfizer maintained its 2026 forecast, but investors remain focused on succession, execution, and competition from obesity-drug makers. Pfizer’s stock has also been affected by concerns over pricing pressure, patent cliffs, and a longer path to profitability in obesity drugs. Meanwhile, Novo Nordisk shares rose about 5% as healthcare stocks gained favor among investors seeking defensive positions, even as the company reported strong demand for its Wegovy pill. Alumis shares surged 15.55% ahead of Phase 2b lupus results due in the third quarter and a planned psoriasis NDA filing in the fourth quarter. Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted application for ONS-5010/LYTENAVA, with a key FDA decision expected on July 29. Other notable moves include AtaiBeckley’s 7.8% rise following the start of its BPL-003 Phase 3 program and CervoMed’s premarket jump after a director-linked trust purchased $3 million in units, following a recent $10.5 million private placement.
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer shares fell 0.4% to $24.90 in after-hours trading after reports the company will lead U.S. drug list-price increases in 2026, including a 15% hike for its COVID vaccine. Healthcare data show Pfizer plans about 80 price increases, as drugmakers prepare for the annual January price reset under political scrutiny. Investors await further pricing updates and Pfizer’s February earnings call.
1 January 2026
···
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept shares plunged nearly 50% to $35.31 after the FDA rejected relacorilant for Cushing’s-related hypertension, citing insufficient evidence of effectiveness. The move erased about $3.7 billion in market value. Corcept said it will meet with the FDA to discuss next steps. The company is also awaiting a July 2026 FDA decision on relacorilant in ovarian cancer.
31 December 2025
··
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab A/S shares fell 3.3% to $30.44 in New York after the company dropped further development of acasunlimab, a late-stage cancer drug, following a portfolio review. Genmab said the move does not affect its 2025 guidance and will focus on other pipeline drugs. The company also completed its acquisition of Merus N.V., paying $97 per share in a tender offer. Merus requested Nasdaq delist its stock after the merger.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharmaceuticals shares rose about 18% in premarket trading after the FDA approved its motion-sickness drug Nereus (tradipitant). The company plans to launch the oral treatment in the coming months. The approval followed late-stage trials involving 681 patients. Shares closed at $7.03 Tuesday and were indicated around $8.30 early Wednesday.
31 December 2025
···
Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer shares slipped 0.02% to $24.99 in late after-hours trading Tuesday. TD Cowen reiterated a Hold rating and $30 price target, citing weak longer-term trends. Investors await Pfizer’s next results for signs it can offset declining COVID sales and upcoming patent expirations. Pfizer forecasts 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00.
31 December 2025
···
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, adding the RIPTAC oncology platform and lead prostate cancer program. Shares slipped 0.3% to $206.91 in after-hours trading. The company expects about $0.20 dilution to adjusted EPS, split between 2025 and 2026, and will discuss 2026 guidance on its Jan. 21 earnings call.
31 December 2025
··
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares edged up 0.1% after hours to $1,079.75 following news it and Novo Nordisk are cutting prices on top obesity drugs in China. Novo confirmed Wegovy price reductions; a hospital WeChat post showed Mounjaro’s 10mg pen dropping to 445 yuan ($63) from 2,180 yuan. Novo’s U.S. shares slipped about 0.5%. Lilly Endowment Inc. disclosed selling 3,593 shares in a regulatory filing.
30 December 2025
···
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
30 December 2025
··
1 … 23 24 25 26 27 … 42

Stock Market Today

  • Ridgetech (RDGT) Stock Surges 68.6% in Nasdaq Premarket on Volume Spike
    June 23, 2026, 8:13 AM EDT. Ridgetech Inc. (Nasdaq: RDGT) shares jumped 68.6% to $2.31 in early premarket trading on June 23, 2026, with a surge in volume to 32.27 million shares. The healthcare distributor, valued at roughly $1.23 million market cap after a recent 1-for-150 reverse split, saw dramatic price swings due to thin trading and low float of fewer than 900,000 shares. The move occurred despite no new company announcements and amid a Nasdaq futures decline. HRT Financial LP, a 10% stakeholder, recently sold about 58,000 shares at $1.60 each. Market experts note the stock's susceptibility to volatility in extended hours and highlight the upcoming test at the regular Nasdaq opening when liquidity increases. Ridgetech operates in pharmaceutical wholesale, retail, and digital platforms in China.

Latest articles

Ridgetech (RDGT) Stock Jumps in Premarket as Volume Surges

Ridgetech (RDGT) Stock Jumps in Premarket as Volume Surges

23 June 2026
Ridgetech shares soared 68.6% to $2.31 in Nasdaq premarket trading on heavy volume, despite no new company news, after a major holder, HRT Financial LP, disclosed selling nearly 58,000 shares last week; with a tiny $1.23 million market cap and under 900,000 shares outstanding, the stock’s price is highly sensitive to trading swings ahead of the regular session open.
Korea Slides 10%, Nasdaq Futures Down 2.7% as Chip Stocks Sink Worldwide

Korea Slides 10%, Nasdaq Futures Down 2.7% as Chip Stocks Sink Worldwide

23 June 2026
Global semiconductor stocks plunged, wiping over $1 trillion from the Nasdaq 100’s market value in premarket trade as investors questioned whether massive AI infrastructure spending by tech giants can deliver returns, with SK Hynix and Samsung Electronics each losing over 12% and Micron set to report results that could further sway memory shares.
Micron Technology Stock Price Falls as $25 Billion Spending Plan Overshadows AI Forecast

Micron Earnings Take Center Stage for AI Stocks This Week

23 June 2026
Micron shares tumbled 8% premarket as investors brace for Wednesday’s earnings, with Wall Street raising the bar above company guidance after a record run; analysts warn that even a beat may disappoint if margins or outlook slip, threatening further stock and sector volatility amid soaring AI memory demand.
Go toTop